Form 4/A for KYNB KYNTRA BIO, INC.
Accepted 2022-12-15 00:00:00 ET · period of report 2022-12-09 · accession 0001209191-22-061485 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MA | 2022-12-15 | 2022-12-09+ | KYNB | Graham Juan | CFO | S - Sale | $14.64 | -2,188 | 48.0K | -4% | -$32.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-09 | S | D | 781 | $14.89 | 49,369 | D | — | — | (F1) Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. (F2) These shares were sold in multiple transactions on the reported date with prices ranging from $14.667 to $14.8936 resulting in a weighted average price of $14.89. Upon request, the reporting person will provide to the Commission staff or a security holder of the Issuer the number of shares sold and the sale price for each separate transaction. |
| 2 | Common | Common Stock | 2022-12-12 | S | D | 1,407 | $14.50 | 47,962 | D | — | — | (F3) Shares sold pursuant to a 10b5-1 plan. |